annual EBITDA:
-$504.55M+$11.91M(+2.31%)Summary
- As of today (July 6, 2025), RARE annual EBITDA is -$504.55 million, with the most recent change of +$11.91 million (+2.31%) on December 31, 2024.
- During the last 3 years, RARE annual EBITDA has fallen by -$94.22 million (-22.96%).
- RARE annual EBITDA is now -7608.86% below its all-time high of -$6.54 million, reached on December 31, 2011.
Performance
RARE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$126.44M-$17.64M(-16.21%)Summary
- As of today (July 6, 2025), RARE quarterly EBITDA is -$126.44 million, with the most recent change of -$17.64 million (-16.21%) on March 31, 2025.
- Over the past year, RARE quarterly EBITDA has increased by +$19.10 million (+13.12%).
- RARE quarterly EBITDA is now -245.53% below its all-time high of $86.88 million, reached on December 31, 2018.
Performance
RARE quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$449.90M+$19.10M(+4.07%)Summary
- As of today (July 6, 2025), RARE TTM EBITDA is -$449.90 million, with the most recent change of +$19.10 million (+4.07%) on March 31, 2025.
- Over the past year, RARE TTM EBITDA has increased by +$69.48 million (+13.38%).
- RARE TTM EBITDA is now -9922.34% below its all-time high of -$4.49 million, reached on December 31, 2012.
Performance
RARE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RARE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.3% | +13.1% | +13.4% |
| 3 y3 years | -23.0% | +10.4% | -5.3% |
| 5 y5 years | -29.4% | -17.4% | -67.3% |
RARE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -23.0% | +21.2% | -24.8% | +42.4% | at high | +29.9% |
| 5 y | 5-year | -260.9% | +21.2% | -438.6% | +42.4% | -221.8% | +29.9% |
| alltime | all time | -7608.9% | +21.2% | -245.5% | +42.4% | -9922.3% | +29.9% |
RARE EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$126.44M(+16.2%) | -$449.90M(-4.1%) |
| Dec 2024 | -$504.55M(-2.3%) | -$108.80M(+0.1%) | -$469.00M(+1.6%) |
| Sep 2024 | - | -$108.74M(+2.7%) | -$461.55M(-5.2%) |
| Jun 2024 | - | -$105.92M(-27.2%) | -$486.94M(-6.2%) |
| Mar 2024 | - | -$145.54M(+43.6%) | -$519.39M(+0.6%) |
| Dec 2023 | -$516.45M(-19.4%) | -$101.35M(-24.4%) | -$516.45M(-5.7%) |
| Sep 2023 | - | -$134.14M(-3.0%) | -$547.56M(-13.5%) |
| Jun 2023 | - | -$138.36M(-3.0%) | -$633.04M(-1.4%) |
| Mar 2023 | - | -$142.60M(+7.7%) | -$642.00M(+0.2%) |
| Dec 2022 | -$640.49M(+56.1%) | -$132.45M(-39.7%) | -$640.49M(+2.8%) |
| Sep 2022 | - | -$219.62M(+49.1%) | -$623.14M(+34.2%) |
| Jun 2022 | - | -$147.33M(+4.4%) | -$464.43M(+8.7%) |
| Mar 2022 | - | -$141.09M(+22.6%) | -$427.43M(+4.2%) |
| Dec 2021 | -$410.32M(+193.5%) | -$115.10M(+88.9%) | -$410.32M(+33.3%) |
| Sep 2021 | - | -$60.92M(-44.8%) | -$307.83M(+1.3%) |
| Jun 2021 | - | -$110.33M(-11.0%) | -$303.77M(+94.6%) |
| Mar 2021 | - | -$123.98M(+883.2%) | -$156.10M(+11.7%) |
| Dec 2020 | -$139.81M(-64.1%) | -$12.61M(-77.8%) | -$139.81M(-35.0%) |
| Sep 2020 | - | -$56.86M(-252.3%) | -$215.14M(-20.0%) |
| Jun 2020 | - | $37.34M(-134.7%) | -$268.83M(-33.3%) |
| Mar 2020 | - | -$107.68M(+22.4%) | -$403.03M(+3.4%) |
| Dec 2019 | -$389.77M(+119.5%) | -$87.94M(-20.5%) | -$389.77M(+81.3%) |
| Sep 2019 | - | -$110.56M(+14.1%) | -$214.95M(+13.3%) |
| Jun 2019 | - | -$96.85M(+2.6%) | -$189.69M(+4.4%) |
| Mar 2019 | - | -$94.42M(-208.7%) | -$181.65M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$177.56M(-43.2%) | $86.88M(-201.9%) | -$177.56M(-49.0%) |
| Sep 2018 | - | -$85.29M(-4.0%) | -$348.15M(+0.8%) |
| Jun 2018 | - | -$88.82M(-1.7%) | -$345.48M(+3.4%) |
| Mar 2018 | - | -$90.33M(+7.9%) | -$334.05M(+6.9%) |
| Dec 2017 | -$312.51M(+27.8%) | -$83.72M(+1.3%) | -$312.51M(+4.8%) |
| Sep 2017 | - | -$82.62M(+6.8%) | -$298.19M(+6.4%) |
| Jun 2017 | - | -$77.39M(+12.5%) | -$280.32M(+7.7%) |
| Mar 2017 | - | -$68.79M(-0.9%) | -$260.30M(+6.4%) |
| Dec 2016 | -$244.58M(+67.1%) | -$69.39M(+7.2%) | -$244.58M(+5.9%) |
| Sep 2016 | - | -$64.75M(+12.9%) | -$230.87M(+12.3%) |
| Jun 2016 | - | -$57.36M(+8.1%) | -$205.61M(+15.4%) |
| Mar 2016 | - | -$53.08M(-4.7%) | -$178.13M(+21.7%) |
| Dec 2015 | -$146.35M(+160.9%) | -$55.68M(+41.0%) | -$146.35M(+36.3%) |
| Sep 2015 | - | -$39.49M(+32.2%) | -$107.41M(+28.5%) |
| Jun 2015 | - | -$29.88M(+40.3%) | -$83.55M(+24.4%) |
| Mar 2015 | - | -$21.30M(+27.3%) | -$67.17M(+19.8%) |
| Dec 2014 | -$56.09M(+76.2%) | -$16.73M(+7.0%) | -$56.09M(+15.0%) |
| Sep 2014 | - | -$15.64M(+15.9%) | -$48.78M(+19.6%) |
| Jun 2014 | - | -$13.50M(+32.1%) | -$40.79M(+15.1%) |
| Mar 2014 | - | -$10.22M(+8.6%) | -$35.44M(+11.3%) |
| Dec 2013 | -$31.84M(+103.1%) | -$9.41M(+22.9%) | -$31.84M(+18.3%) |
| Sep 2013 | - | -$7.66M(-6.0%) | -$26.91M(+39.8%) |
| Jun 2013 | - | -$8.14M(+23.0%) | -$19.26M(+73.3%) |
| Mar 2013 | - | -$6.62M(+47.5%) | -$11.11M(+147.5%) |
| Dec 2012 | -$15.67M(+139.4%) | -$4.49M | -$4.49M |
| Dec 2011 | -$6.54M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual EBITDA?
- What is the all time high annual EBITDA for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual EBITDA year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly EBITDA year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM EBITDA year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual EBITDA?
The current annual EBITDA of RARE is -$504.55M
What is the all time high annual EBITDA for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual EBITDA is -$6.54M
What is Ultragenyx Pharmaceutical Inc. annual EBITDA year-on-year change?
Over the past year, RARE annual EBITDA has changed by +$11.91M (+2.31%)
What is Ultragenyx Pharmaceutical Inc. quarterly EBITDA?
The current quarterly EBITDA of RARE is -$126.44M
What is the all time high quarterly EBITDA for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly EBITDA is $86.88M
What is Ultragenyx Pharmaceutical Inc. quarterly EBITDA year-on-year change?
Over the past year, RARE quarterly EBITDA has changed by +$19.10M (+13.12%)
What is Ultragenyx Pharmaceutical Inc. TTM EBITDA?
The current TTM EBITDA of RARE is -$449.90M
What is the all time high TTM EBITDA for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM EBITDA is -$4.49M
What is Ultragenyx Pharmaceutical Inc. TTM EBITDA year-on-year change?
Over the past year, RARE TTM EBITDA has changed by +$69.48M (+13.38%)